Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2

Journal of Interferon and Cytokine Research

Volumn 18, Issue 11, 1998, Pages 927-937

  Emtage, Peter C R ^a   Wan, Yonghong ^a   Muller, William ^a   Graham, Frank L ^a   Gauldie, Jack ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b Department of Pathology ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE EXPRESSION; GENE TRANSFER; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ADENOVIRIDAE; ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0031649119     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.927     Document Type: Article

References (83)

1. BRETSCHER, P., and COHN, M. (1970). A theory of self-non-self discrimination. Science 169, 1042-1049.
2. LAFFERTY, K.J., and GILL, R.G. (1993). The maintenance of self-tolerance. Immunol. Cell Biol. 71, 209-214.
3. BOUSSIOTIS, V.A., FREEMAN, G.J., GRIEBEN, J.G., and NADLER, L.M. (1996). The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol. Rev. 153, 5-26.
4. SCHULTZE, J., NADLER, L.M., and GRIEBEN, J.G. (1996). B7-mediated costimulation and the immune response. Blood Rev. 10, 111-127.
5. GUINAN, E.C., GRIBBEN, J.G., BOUSSIOTIS, V.A., FREEMAN, G.J., and NADLER, L.M. (1994). Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261-3282.
6. LIU, Y., and LINSLEY, P.S. (1992). Costimulation of T-cell growth. Curr. Opin. Immunol. 4, 265-270.
7. JUNE, C.H., BLUESTONE, J.A., NADLER, L.M., and THOMPSON, C.B. (1994). The B7 and CD28 receptor families. Immunol. Today 15, 321-331.
8. SCHWARTZ, R.H. (1990). A cell culture model for T lymphocyte clonal anergy. Science 248, 1349-1356.
9. JENKINS, M.K., and MILLER, R.A. (1992). Memory and anergy: challenges to traditional models of T lymphocyte differentiation. FASEB J. 6, 2428-2433.
10. FREEMAN, G.J., FREEDMAN, A.S., SEGIL, J.M., LEE, G., WHITMAN, J.F., and NADLER, L.M. (1989). B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143, 2714-2722.
11. FREEMAN, G.J., GRAY, G.S., GIMMI, C.D., LOMBARD, D.B., ZHOU, L.J., WHITE, M., FINGEROTH, J.D., GRIEBEN, J.G., and NADLER, L.M. (1991). Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174, 625-631.
12. LINSLEY, P.S., CLARK, E.A., and LEDBETTER, J.A. (1990). T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc. Natl. Acad. Sci. USA 87, 5031-5035.
13. BRUNET, J.F., DENIZOT, F., LUCIANI, M.F., ROUX-DOSSETO, M., SUZAN, M., MATTEI, M.G., and GOLSTEIN, P. (1987). A new member of the immunoglobulin superfamily - CTLA-4. Nature 328, 267-270.
14. FREEDMAN, A.S., FREEMAN, G., HOROWITZ, J.C., DALEY, J., and NADLER, L.M. (1987). B7, a B-cell-restricted antigen that identifies preactivated B cells. J. Immunol. 139, 3260-3267.
15. YOKOCHI, T., HOLLY, R.D., and CLARK, E.A. (1982). B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J. Immunol. 128, 823-827.
16. CERDAN, C., MARTIN, Y., COURCOUL, M., BRAILLY, H., MAWAS, C., BIRG, F., and OLIVE, D. (1992). Prolonged IL-2 receptor alpha/CD25 expression after T cell activation via the adhesion molecules CD2 and CD28. Demonstration of combined transcriptional and post-transcriptional regulation. J. Immunol. 149, 2255-2261.
17. GALVIN, F., FREEMAN, G.J., RAZI-WOLF, Z., HALL, W.J., BENACERRAE, B., NADLER, L., and REISER, H. (1992). Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation. J. Immunol. 149, 3802-3808.
18. CERDAN, C., MARTIN, Y., COURCOUL, M., MAWAS, C., BIRG, F., and OLIVE, D. (1995). CD28 costimulation regulates long-term expression of the three genes (alpha, beta, gamma) encoding the high-affinity IL2 receptor. Res. Immunol. 146, 164-168.
19. JUNE, C.H., JACKSON, K.M., LEDBETTER, J.A., LEIDEN, J.M., LINDSTEN, T., and THOMPSON, C.B. (1989). Two distinct mechanisms of interleukin-2 gene expression in human T lymphocytes. J. Autoimmun. 2(Suppl.), 55-65.
20. THOMPSON, C.B., LINDSTEN, T., LEDBETTER, J.A., KUNKEL, S.L., YOUNG, H.A., EMERSON, S.G., LEIDEN, J.M., and JUNE, C.H. (1989). CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA 86, 1333-1337.
21. FRASER, J.D., IRVING, B.A., CRABTREE, G.R., and WEISS, A. (1991). Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 251, 313-316.
22. FRASER, J.D., and WEISS, A. (1992). Regulation of T-cell lymphokine gene transcription by the accessory molecule CD28. Mol. Cell. Biol. 12, 4357-4363.
23. FREEMAN, G.J., LOMBARD, D.B., GIMMI, C.D., BROD, S.A., LEE, K., LANING, J.C., HAFLER, D.A., DORF, M.E., GRAY, G.S., and REISER, H. (1992). CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J. Immunol. 149, 3795-3801.
24. LINDSTEN, T., LEE, K.P., HARRIS, E.S., PETRYNIAK, B., CRAIGHEAD, N., REYNOLDS, P.J., LOMBARD, D.B., FREEMAN, G.J., NADLER, L.M., and GRAY, G.S. (1993). Characterization of CTLA-4 structure and expression on human T cells. J. Immunol. 151, 3489-3499.
25. GIMMI, C.D., FREEMAN, G.J., GRIBBEN, J.G., SUGITA, K., FREEDMAN, A.S., MORIMOTO, C., and NADLER, L.M. (1991). B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc. Natl. Acad. Sci. USA 88, 6575-6579.
26. LINSLEY, P.S., BRADY, W., GROSMAIRE, L., ARUFFO, A., DAMLE, N.K., and LEDBETTER, J.A. (1991). Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173, 721-730.
27. FREEMAN, G.J., BORRIELLO, F., HODES, R.J., REISER, H., GRIBBEN, J.G., NG, J.W., KIM, J., GOLDBERG, J.M., HATHCOCK, K., and LASZLO, G. (1993). Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178, 2185-2192.
28. FREEMAN, G.J., GRIBBEN, J.G., BOUSSIOTIS, V.A., NG, J.W., RESTIVO, V.A.J., LOMBARD, L.A., GRAY, G.S., and NADLER, L.M. (1993). Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation [see Comments]. Science 262, 909-911.
29. LINSLEY, P.S., WALLACE, P.M., JOHNSON, J., GIBSON, M.G., GREENE, J.L., LEDBETTER, J.A., SINGH, C., and TEPPER, M.A. (1992). Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257, 792-795.
30. BLAZAR, B.R., TAYLOR, P.A., LINSLEY, P.S., and VALLERA, D.A. (1994). In vivo blockade of CD28/CTLA4:B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83, 3815-3825.
31. LENSCHOW, D.J., ZENG, Y., THISTLETHWAITE, J.R., MONTAG, A., BRADY, W., GIBSON, M.G., LINSLEY, P.S., and BLUESTONE, J.A. (1992). Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig [see Comments]. Science 257, 789-792.
32. LIN, H., BOLLING, S.F., LINSLEY, P.S., WEI, R.Q., GORDON, D., THOMPSON, C.B., and TURKA, L.A. (1993). Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 178, 1801-1806.
33. MILICH, D.R., LINSLEY, P.S., HUGHES, J.L., and JONES, J.E. (1994). Soluble CTLA-4 can suppress autoantibody production and elicit long-term unresponsiveness in a novel transgenic model. J. Immunol. 153, 429-435.
34. FINCK, B.K., LINSLEY, P.S., and WOFSY, D. (1994). Treatment of murine lupus with CTLA4Ig. Science 265, 1225-1227.
35. CHEN, L., ASHE, S., BRADY, W.A., HELLSTROM, I., HELLSTROM, K.E., LEDBETTER, J.A., McGOWAN, P., and LINSLEY, P.S. (1992). Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102.
36. + T cells by B7-transfected melanoma cells [see Comments]. Science 259, 368-370.
37. YANG, G., HELLSTROM, K.E., HELLSTROM, I., and CHEN, L. (1995). Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154, 2794-2800.
38. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153, 421-428.
39. RAMARATHINAM, L., CASTLE, M., WU, Y., and LIU, Y. (1994). T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179, 1205-1214.
40. TOWNSEND, S.E., SU, F.W., ATHERTON, J.M., and ALLISON, J.P. (1994). Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54, 6477-6483.
41. LA MOTTE, R.N., RUBIN, M.A., BARR, E., LEIDEN, J.M., BLUESTONE, J.A., and MOKYR, M.B. (1996). Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol. Immunother. 42, 161-169.
42. CHONG, H., HUTCHINSON, G., HART, I.R., and VILE, R.G. (1996). Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity. Hum. Gene Ther. 7, 1771-1779.
43. CHONG, H., TODRYK, S., HUTCHINSON, G., HART, I.R., and VILE, R.G. (1998). Tumor cell expression of B7 constimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity [In Process Citation]. Gene Ther. 5, 223-232.
44. FREEMAN, G.J., BOUSSIOTIS, V.A., ANUMANTHAN, A., BERNSTEIN, G.M., KE, X.Y., RENNERT, P.D., GRAY, G.S., GRIBBEN, J.G., and NADLER, L.M. (1995). B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2, 523-532.
45. LENSCHOW, D.J., HO, S.C., SATTAR, H., RHEE, L., GRAY, G., NABAVI, N., HEROLD, K.C., and BLUESTONE, J.A. (1995). Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181, 1145-1155.
46. KUCHROO, V.K., DAS, M.P., BROWN, J.A., RANGER, A.M., ZAMVIL, S.S., SOBEL, R.A., WEINER, H.L., NABAVI, N., and GLIMCHER, L.H. (1995). B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80, 707-718.
47. LANIER, L.L., O'FALLON, S., SOMOZA, C., PHILLIPS, J.H., LINSLEY, P.S., OKUMURA, K., ITO, D., and AZUMA, M. (1995). CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 154, 97-105.
48. + T cells and induce similar patterns of cytokine secretion in vitro. Int. Immunol. 7, 891-904.
49. SCHWEITZER, A.N., BORRIELLO, F., WONG, R.C., ABBAS, A.K., and SHARPE, A.H. (1997). Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86. J. Immunol. 158, 2713-2722.
50. + T lymphocytes in the P815 tumor system in vitro. J. Immunol. 156, 465-472.
51. MATULONIS, U., DOSIOU, C., FREEMAN, G., LAMONT, C., MAUCH, P., NADLER, L.M., and GRIFFIN, J.D. (1996). B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156, 1126-1131.
52. MARTIN-FONTECHA, A., CAVALLO, F., BELLONE, M., HELTAI, S., EEZZI, G., TORNAGHI, P., NABAVI, N., FORNI, G., DELLABONA, P., and CASORATI, G. (1996). Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur. J. Immunol. 26, 1851-1859.
53. EMTAGE, P.C., WAN, Y., BRAMSON, J.L., GRAHAM, F.L., and GAULDIE, J. (1998). A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. J. Immunol. 160, 2531-2538.
54. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
55. GRAHAM, F.L. (1987). Growth of 293 cells in suspension culture. J. Gen. Virol. 68, 937-940.
56. SIEGEL, P.M., DANKORT, D.L., HARDY, W.R., and MULLER, W.J. (1994). Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol. 14, 7068-7077.
57. SIEGEL, P.M., and MULLER, W.J. (1996). Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Proc. Natl. Acad. Sci. USA 93, 8878-8883.
58. PUTZER, B.M., BRAMSON, J.L., ADDISON, C.L., HITT, M., SIEGEL, P.M., MULLER, W.J., and GRAHAM, F.L. (1998). Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer [In Process Citation]. Hum. Gene Ther. 9, 707-718.
59. BETT, A.J., HADDARA, W., PREVEC, L., and GRAHAM, F.L. (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA 91, 8802-8806.
60. ADDISON, C.L., BRACIAK, T., RALSTON, R., MULLER, W.J., GAULDIE, J., and GRAHAM, F.L. (1995). Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sci. USA 92, 8522-8526.
61. GUY, C.T., CARDIFF, R.D., and MULLER, W.J. (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12, 954-961.
62. JANG, S.K., KRAUSSLICH, H.G., NICKLIN, M.J., DUKE, G.M., PALMENBERG, A.C., and WIMMER, E. (1988). A segment of the 5′-nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J. Virol. 62, 2636-2643.
63. BRAMSON, J., HITT, M., GALLICHAN, W.S., ROSENTHAL, K.L., GAULDIE, J., and GRAHAM, F.L. (1996). Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum. Gene Ther. 7, 333-342.
64. CHEN, L., LINSLEY, P.S., and HELLSTROM, K.E. (1993). Costimulation of T cells for tumor immunity. Immunol. Today 14, 483-486.
65. BASKAR, S., OSTRAND-ROSENBERG, S., NABAVI, N., NADLER, L.M., FREEMAN, G.J., and GLIMCHER, L.H. (1993). Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90, 5687-5690.
66. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177, 1791-1796.
67. HARDING, F.A., McARTHUR, J.G., GROSS, J.A., RAULET, D.H., and ALLISON, J.P. (1992). CD28-mediated signalling costimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356, 607-609.
68. GIMMI, C.D., FREEMAN, G.J., GRIBBEN, J.G., GRAY, G., and NADLER, L.M. (1993). Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA 90, 6586-6590.
69. BOUSSIOTIS, V.A., FREEMAN, G.J., GRIEBEN, J.G., DALEY, J., GRAY, G., and NADLER, L.M. (1993). Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc. Natl. Acad. Sci. USA 90, 11059-11063.
70. CHEN, L., McGOWAN, P., ASHE, S., JOHNSTON, J., LI, Y., HELLSTROM, I., and HELLSTROM, K.E. (1994). Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp. Med. 179, 523-532.
71. MATULONIS, U.A., DOSIOU, C., LAMONT, C., FREEMAN, G.J., MAUCH, P., NADLER, L.M., and GRIFFIN, J.D. (1995). Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85, 2507-2515.
72. ZITVOGEL, L., ROBBINS, P.D., STORKUS, W.J., CLARKE, M.R., MAEURER, M.J., CAMPBELL, R.L., DAVIS, C.G., TAHARA, H., SCHREIBER, R.D., and LOTZE, M.T. (1996). Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol. 26, 1335-1341.
73. PUTZER, B.M., HITT, M., MULLER, W.J., EMTAGE, P., GAULDIE, J., and GRAHAM, F.L. (1997). Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sci. USA 94, 10889-10894.
74. SALVADORI, S., GANSBACHER, B., WERNICK, I., TIRELLI, S., and ZIER, K. (1995). B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. Hum. Gene Ther. 6, 1299-1306.
75. CAYEUX, S., BECK, C., AICHER, A., DORKEN, B., and BLANKENSTEIN, T. (1995). Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur. J. Immunol. 25 ,2325-2331.
76. + cells: the role of CD28 costimulation. Scand. J. Immunol. 44, 21-29.
77. ROSENBERG, S.A., PACKARD, B.S., AEBERSOLD, P.M., SOLOMON, D., TOPALIAN, S.L., TOY, S.T., SIMON, P., LOTZE, M.T., YANG, J.C., and SEIPP, C.A. (1988). Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319, 1676-1680.
78. ROSENBERG, S.A., LOTZE, M.T., MUUL, L.M., LEITMAN, S., CHANG, A.E., ETTINGHAUSEN, S.E., MATORY, Y.L., SKIBBER, J.M., SHILONI, E., and VETTO, J.T. (1985). Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485-1492.
79. LEONG, C.C., MARLEY, J.V., LOH, S., MILECH, N., ROBINSON, B.W., and GARLEPP, M.J. (1997). Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma. Int. J. Cancer 71, 476-482.
80. NUNES, J.A., BATTIFORA, M., VVOODGETT, J.R., TRUNEH, A., OLIVE, D., and CANTRELL, D.A. (1996). CD28 signal transduction pathways. A comparison of B7-1 and B7-2 regulation of the map kinases: ERK2 and Jun kinases. Mol. Immunol. 33, 63-70.
81. NUNES, J.A., TRUNEH, A., OLIVE, D., and CANTRELL, D.A. (1996). Signal transduction by CD28 costimulatory receptor on T cells. B7-1 and B7-2 regulation of tyrosine kinase adaptor molecules. J. Biol. Chem. 271, 1591-1598.
82. LINSLEY, P.S., GREENE, J.L. , BRADY, W., BAJORATH, J., LEDBETTER, J.A., AND PEACH, R. (1994). Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1, 793-801.
83. BORIELLO, F., FREEMAN, G.J., EDELHOFF, S., DISTECHE, C.M., NADLER, L.M., AND SHARPE, A.H. (1994). Characterization of the murine B7-1 genomic locus reveals an additional exon encoding an alternative cytoplasmic domain and a chromosomal location of chromosome 16, band B5. J. Immunol. 153, 5038-5048.